Literature DB >> 18424258

Osteoclast lineage and function.

H Kalervo Väänänen1, Tiina Laitala-Leinonen.   

Abstract

Osteoclasts are members of the monocyte/macrophage lineage and are formed by cellular fusions from their mononuclear precursors. Their differentiation is regulated by a number of other cells and their products, especially by RANKL and M-CSF. The resorbing osteoclasts are polarized and show specific plasma membrane domains. Polarization and bone resorption need a continuous membrane trafficking and modulation of the cytoskeleton. The most characteristic feature of osteoclasts is their unique capacity to dissolve crystalline hydroxyapatite by targeted secretion of HCl into the extracellular resorption lacuna. Organic matrix is degraded by enzymes like cathepsin K and the degradation products are transcytosed through the cell for secretion. Dissolution of hydroxyapatite releases large amounts of soluble calcium, phosphate and bicarbonate. Removal of these ions apparently involves the vesicular pathways and direct ion transport via different ion exchangers, channels and pumps. Detailed molecular knowledge of osteoclast differentiation and function has helped us to identify several target molecules and develop specific treatments to inhibit pathological bone resorption in various skeletal diseases.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18424258     DOI: 10.1016/j.abb.2008.03.037

Source DB:  PubMed          Journal:  Arch Biochem Biophys        ISSN: 0003-9861            Impact factor:   4.013


  65 in total

1.  Spontaneous and induced osteoclastogenic behaviour of human peripheral blood mononuclear cells and their CD14(+) and CD14(-) cell fractions.

Authors:  J Costa-Rodrigues; A Fernandes; M H Fernandes
Journal:  Cell Prolif       Date:  2011-10       Impact factor: 6.831

2.  Pasteurella multocida toxin-stimulated osteoclast differentiation is B cell dependent.

Authors:  Dagmar Hildebrand; Klaus Heeg; Katharina F Kubatzky
Journal:  Infect Immun       Date:  2010-10-18       Impact factor: 3.441

3.  RAF265, a dual BRAF and VEGFR2 inhibitor, prevents osteoclast formation and resorption. Therapeutic implications.

Authors:  Antonio Garcia-Gomez; Enrique M Ocio; Atanasio Pandiella; Jesús F San Miguel; Mercedes Garayoa
Journal:  Invest New Drugs       Date:  2012-07-07       Impact factor: 3.850

Review 4.  The molecular mechanism behind bone remodelling: a review.

Authors:  Peter Proff; Piero Römer
Journal:  Clin Oral Investig       Date:  2009-03-25       Impact factor: 3.573

5.  Periodontal inflammation and alveolar bone loss induced by Aggregatibacter actinomycetemcomitans is attenuated in sphingosine kinase 1-deficient mice.

Authors:  H Yu; C Sun; K M Argraves
Journal:  J Periodontal Res       Date:  2015-04-20       Impact factor: 4.419

6.  Rosmarinic acid and arbutin suppress osteoclast differentiation by inhibiting superoxide and NFATc1 downregulation in RAW 264.7 cells.

Authors:  Akina Omori; Yoshitaka Yoshimura; Yoshiaki Deyama; Kuniaki Suzuki
Journal:  Biomed Rep       Date:  2015-04-17

7.  Potential role of cathepsin K in the pathophysiology of mucopolysaccharidoses.

Authors:  Susan Wilson; Dieter Brömme
Journal:  J Pediatr Rehabil Med       Date:  2010

8.  BIX01294 suppresses osteoclast differentiation on mouse macrophage-like Raw264.7 cells.

Authors:  Hiromasa Tsuda; Ning Zhao; Kenichi Imai; Kuniyasu Ochiai; Pishan Yang; Naoto Suzuki
Journal:  Bosn J Basic Med Sci       Date:  2013-11       Impact factor: 3.363

Review 9.  Is interaction between age-dependent decline in mechanical stimulation and osteocyte-estrogen receptor levels the culprit for postmenopausal-impaired bone formation?

Authors:  R Sapir-Koren; G Livshits
Journal:  Osteoporos Int       Date:  2012-11-15       Impact factor: 4.507

10.  Identification of a novel L-serine analog that suppresses osteoclastogenesis in vitro and bone turnover in vivo.

Authors:  Anton Bahtiar; Takahiro Matsumoto; Takashi Nakamura; Motofusa Akiyama; Keiichiro Yogo; Norihiro Ishida-Kitagawa; Takuya Ogawa; Tatsuo Takeya
Journal:  J Biol Chem       Date:  2009-10-16       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.